PDE6G

Summary

PDE6G (phosphodiesterase 6G, HGNC:8789) is a protein-coding gene on chromosome 17q25.3, encoding Retinal rod rhodopsin-sensitive cGMP 3’,5’-cyclic phosphodiesterase subunit gamma (P18545). Participates in processes of transmission and amplification of the visual signal. cGMP-PDEs are the effector molecules in G-protein-mediated phototransduction in vertebrate rods and cones.

This gene encodes the gamma subunit of cyclic GMP-phosphodiesterase, which is composed of alpha- and beta- catalytic subunits and two identical, inhibitory gamma subunits. This gene is expressed in rod photoreceptors and functions in the phototransduction signaling cascade. It is also expressed in a variety of other tissues, and has been shown to regulate the c-Src protein kinase and G-protein-coupled receptor kinase 2. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 5148 — RefSeq curated summary.

At a glance

• Gene–disease (curated): PDE6G-related retinopathy (Definitive, ClinGen) — +2 more curated relationships
• GWAS associations: 3
• Clinical variants (ClinVar): 114 total — 4 pathogenic
• Phenotypes (HPO): 39
• Druggable target: yes — 6 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_002602

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:8789
Approved symbol	PDE6G
Name	phosphodiesterase 6G
Location	17q25.3
Locus type	gene with protein product
Status	Approved
Aliases	RP57
Ensembl gene	ENSG00000185527
Ensembl biotype	protein_coding
OMIM	180073
Entrez	5148

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 8 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000331056, ENST00000571004, ENST00000571224, ENST00000574024, ENST00000574777, ENST00000862059, ENST00000862060, ENST00000916622, ENST00000916623, ENST00000916624

RefSeq mRNA: 3 — MANE Select: NM_002602 NM_001365724, NM_001365725, NM_002602

CCDS: CCDS11783

Canonical transcript exons

ENST00000331056 — 4 exons

Exon	Start	End
ENSE00001693839	81656493	81656542
ENSE00003464626	81651645	81651685
ENSE00003601492	81653160	81653364
ENSE00003613115	81650459	81651150

Expression profiles

Bgee: expression breadth ubiquitous, 163 present calls, max score 89.99.

FANTOM5 (CAGE): breadth broad, TPM avg 4.1158 / max 2936.6600, expressed in 435 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
168775	2.7307	14
168774	1.0929	422
168776	0.2921	9

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	89.99	silver quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	87.88	gold quality
endometrium epithelium	UBERON:0004811	84.01	gold quality
granulocyte	CL:0000094	82.83	gold quality
lymph node	UBERON:0000029	82.83	gold quality
spleen	UBERON:0002106	81.06	gold quality
pigmented layer of retina	UBERON:0001782	79.20	gold quality
monocyte	CL:0000576	78.69	gold quality
leukocyte	CL:0000738	78.29	gold quality
mononuclear cell	CL:0000842	78.14	gold quality
epithelial cell of pancreas	CL:0000083	77.86	gold quality
parotid gland	UBERON:0001831	77.31	gold quality
secondary oocyte	CL:0000655	76.87	silver quality
olfactory bulb	UBERON:0002264	76.71	gold quality
blood	UBERON:0000178	75.36	gold quality
type B pancreatic cell	CL:0000169	74.99	gold quality
male germ cell	CL:0000015	74.28	gold quality
mucosa of paranasal sinus	UBERON:0005030	74.01	gold quality
sperm	CL:0000019	74.00	gold quality
vastus lateralis	UBERON:0001379	73.84	gold quality
bone marrow cell	CL:0002092	73.60	gold quality
bone marrow	UBERON:0002371	72.89	gold quality
quadriceps femoris	UBERON:0001377	72.88	gold quality
cervix squamous epithelium	UBERON:0006922	72.79	gold quality
vermiform appendix	UBERON:0001154	72.70	gold quality
cerebellar vermis	UBERON:0004720	72.27	gold quality
placenta	UBERON:0001987	72.19	gold quality
caecum	UBERON:0001153	71.89	gold quality
hair follicle	UBERON:0002073	71.74	gold quality
periodontal ligament	UBERON:0008266	70.91	silver quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-MTAB-7316	yes	26432.59
E-GEOD-137537	yes	12540.47
E-GEOD-135922	yes	12048.69
E-GEOD-98556	yes	2501.46
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 5)

• PDEG functions to link c-Src and G-protein-coupled receptor kinase 2 in a signaling unit that regulates p42/p44 mitogen-activated protein kinase by epidermal growth factor (PMID:12624098)
• Crystal structures of a chimaeric PDE5/PDE6 catalytic domain (PDE5/6cd) complexed with sildenafil or 3-isobutyl-1-methylxanthine and the Pgamma-inhibitory peptide Pgamma(70-87) have been determined at 2.9 and 3.0 A, respectively. (PMID:19798052)
• The C-terminus of PED gamma occludes the active site of PDE6, thereby preventing hydrolysis of cGMP. (PMID:20397626)
• These findings demonstrate the positive role of the gamma subunit in maintaining phosphodiesterase activity and confirm the contribution of PDE6G to the etiology of retinitis pigmentosa in humans. (PMID:20655036)
• Collectively, we report previously unrecognized PDE6 expression in human lungs, significant alterations of the PDE6D and PDE6G/H subunits in IPF lungs. (PMID:20979602)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	pde6gb	ENSDARG00000101984
mus_musculus	Pde6g	ENSMUSG00000025386
rattus_norvegicus	Pde6g	ENSRNOG00000069361

Paralogs (1): PDE6H (ENSG00000139053)

Protein

Protein identifiers

Retinal rod rhodopsin-sensitive cGMP 3’,5’-cyclic phosphodiesterase subunit gamma — P18545 (reviewed: P18545)

All UniProt accessions (1): P18545

UniProt curated annotations — full annotation on UniProt →

Function. Participates in processes of transmission and amplification of the visual signal. cGMP-PDEs are the effector molecules in G-protein-mediated phototransduction in vertebrate rods and cones.

Subunit / interactions. Oligomer composed of two catalytic chains (alpha and beta), an inhibitory chain (gamma) and the delta chain.

Disease relevance. Retinitis pigmentosa 57 (RP57) [MIM:613582] A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the rod/cone cGMP-PDE gamma subunit family.

RefSeq proteins (3): NP_001352653, NP_001352654, NP_002593* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006952	PDE6_gamma	Family
IPR037030	PDE6_gamma_sf	Homologous_superfamily

Pfam: PF04868

Catalyzed reactions (Rhea), 1 shown:

• 3’,5’-cyclic GMP + H2O = GMP + H(+) (RHEA:16957)

UniProt features (8 total): compositionally biased region 2, chain 1, region of interest 1, modified residue 1, sequence variant 1, turn 1, helix 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
3JWR	X-RAY DIFFRACTION	2.99

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P18545-F1	67.73	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 1

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-2485179	Activation of the phototransduction cascade
R-HSA-2514859	Inactivation, recovery and regulation of the phototransduction cascade
R-HSA-4086398	Ca2+ pathway

MSigDB gene sets: 178 (showing top): GRUETZMANN_PANCREATIC_CANCER_DN, GOBP_REGULATION_OF_ERBB_SIGNALING_PATHWAY, GOBP_POSITIVE_REGULATION_OF_MAPK_CASCADE, GOBP_ERBB_SIGNALING_PATHWAY, GOBP_SENSORY_PERCEPTION_OF_LIGHT_STIMULUS, DAVIES_MULTIPLE_MYELOMA_VS_MGUS_UP, GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, KEGG_PURINE_METABOLISM, GOBP_SENSORY_PERCEPTION, GOCC_NEURON_PROJECTION, GOBP_POSITIVE_REGULATION_OF_ERBB_SIGNALING_PATHWAY, NIKOLSKY_BREAST_CANCER_17Q21_Q25_AMPLICON, GCM_VAV1, SHEN_SMARCA2_TARGETS_DN, GOCC_CELL_PROJECTION_MEMBRANE

GO Biological Process (4): visual perception (GO:0007601), positive regulation of MAPK cascade (GO:0043410), positive regulation of epidermal growth factor receptor signaling pathway (GO:0045742), positive regulation of G protein-coupled receptor signaling pathway (GO:0045745)

GO Molecular Function (7): enzyme inhibitor activity (GO:0004857), spectrin binding (GO:0030507), cGMP binding (GO:0030553), 3’,5’-cyclic-GMP phosphodiesterase activity (GO:0047555), 3’,5’-cyclic-nucleotide phosphodiesterase activity (GO:0004114), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (3): plasma membrane (GO:0005886), photoreceptor outer segment membrane (GO:0042622), photoreceptor disc membrane (GO:0097381)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
The phototransduction cascade	2
Beta-catenin independent WNT signaling	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
catalytic activity	2
photoreceptor outer segment	2
sensory perception of light stimulus	1
MAPK cascade	1
regulation of MAPK cascade	1
positive regulation of intracellular signal transduction	1
epidermal growth factor receptor signaling pathway	1
regulation of epidermal growth factor receptor signaling pathway	1
positive regulation of ERBB signaling pathway	1
G protein-coupled receptor signaling pathway	1
regulation of G protein-coupled receptor signaling pathway	1
positive regulation of signal transduction	1
enzyme regulator activity	1
molecular function inhibitor activity	1
cytoskeletal protein binding	1
protein-containing complex binding	1
cyclic nucleotide binding	1
guanyl ribonucleotide binding	1
anion binding	1
3’,5’-cyclic-nucleotide phosphodiesterase activity	1
cyclic-nucleotide phosphodiesterase activity	1
binding	1
membrane	1
cell periphery	1
ciliary membrane	1
organelle membrane	1

Protein interactions and networks

STRING

753 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PDE6G	PDE6A	P16499	980
PDE6G	PDE6B	P35913	949
PDE6G	CNGA1	P29973	798
PDE6G	ZNF513	Q8N8E2	792
PDE6G	PRPH2	P23942	782
PDE6G	PCARE	A6NGG8	779
PDE6G	PRCD	Q00LT1	779
PDE6G	IMPG2	Q9BZV3	775
PDE6G	CNGB1	Q14028	756
PDE6G	GUCA1B	Q9UMX6	752
PDE6G	CERKL	Q49MI3	739
PDE6G	FSCN2	O14926	728
PDE6G	IDH3B	O43837	725
PDE6G	EYS	Q5T1H1	725
PDE6G	ROM1	Q03395	723

IntAct

29 interactions, top by confidence:

A	B	Type	Score
PDE6G	Pacsin2	psi-mi:“MI:0915”(physical association)	0.630
PDE6G	Pacsin2	psi-mi:“MI:0407”(direct interaction)	0.630
Pacsin2	PDE6G	psi-mi:“MI:0915”(physical association)	0.630
PDE6G	BHLHE40	psi-mi:“MI:0915”(physical association)	0.560
PDE6G	L3MBTL3	psi-mi:“MI:0915”(physical association)	0.560
BHLHE40	PDE6G	psi-mi:“MI:0915”(physical association)	0.560
L3MBTL3	PDE6G	psi-mi:“MI:0915”(physical association)	0.560
PRKAB2	PDE6G	psi-mi:“MI:0915”(physical association)	0.560
PDE6G		psi-mi:“MI:0915”(physical association)	0.560
PDE6G	PMP22	psi-mi:“MI:0915”(physical association)	0.560
Grb2	PDE6G	psi-mi:“MI:0915”(physical association)	0.530
Pik3r1	PDE6G	psi-mi:“MI:0915”(physical association)	0.530
PDE6G	Fnbp1	psi-mi:“MI:0915”(physical association)	0.530
Grb2	PDE6G	psi-mi:“MI:0407”(direct interaction)	0.530
PDE6G	Pik3r1	psi-mi:“MI:0407”(direct interaction)	0.530
Fnbp1	PDE6G	psi-mi:“MI:0407”(direct interaction)	0.530
PDE6G	gB	psi-mi:“MI:0915”(physical association)	0.370
PDE6G	Src	psi-mi:“MI:0915”(physical association)	0.370
PDE6G	Bin1	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (12): BHLHE40 (Two-hybrid), L3MBTL3 (Two-hybrid), PDE6G (Affinity Capture-Western), PDE6G (Affinity Capture-Western), SRC (Affinity Capture-Western), ADRBK1 (Affinity Capture-Western), ADRBK1 (Reconstituted Complex), SRC (Reconstituted Complex), GRB2 (Reconstituted Complex), DNM2 (Reconstituted Complex), PDE6G (Two-hybrid), SRRT (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A0MD36, A1DL98, F1QGC8, O54842, O60356, O89085, O95182, P09511, P0DTP1, P0DTP2, P18545, P19810, P20290, P22571, P35940, P61249, P61250, P75347, Q04558, Q05752, Q06616, Q0MQA7, Q0MQA8, Q0VCV7, Q1KN16, Q1KN19, Q1KN21, Q1X6Y4, Q1X6Y6, Q1X6Z0, Q1X6Z2, Q1X6Z4, Q1X709, Q1X711, Q2T9V8, Q2U6N1, Q3KPS4, Q5VKP5, Q5ZK14, Q64152

Diamond homologs: O55175, P04972, P09174, P18545, P22571, P54827, P61248, P61249, P61250, Q13956, Q9EQQ8

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
GRK2	“up-regulates activity”	PDE6G	phosphorylation
PDE6G	“down-regulates activity”	PDE6A	binding
GNAT1	“down-regulates activity”	PDE6G	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

114 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	4
Likely pathogenic	0
Uncertain significance	57
Likely benign	39
Benign	9

Top pathogenic / likely-pathogenic (4)

Variant ID	HGVS	Classification
13102	NM_002602.4(PDE6G):c.187+1G>T	Pathogenic
1465534	NM_002602.4(PDE6G):c.69dup (p.Arg24fs)	Pathogenic
1943178	NM_002602.4(PDE6G):c.97C>T (p.Arg33Ter)	Pathogenic
3250311	NM_002602.4(PDE6G):c.146+1G>T	Pathogenic

SpliceAI

499 predictions. Top by Δscore:

Variant	Effect	Δscore
17:81651148:TGT:T	acceptor_gain	1.0000
17:81651151:C:CA	acceptor_loss	1.0000
17:81651151:C:CC	acceptor_gain	1.0000
17:81651146:GATGT:G	acceptor_gain	0.9900
17:81651147:ATGT:A	acceptor_gain	0.9900
17:81651149:GT:G	acceptor_gain	0.9900
17:81651642:TA:T	donor_loss	0.9900
17:81651643:A:C	donor_loss	0.9900
17:81651644:C:A	donor_loss	0.9900
17:81653158:AC:A	donor_gain	0.9900
17:81653159:CC:C	donor_gain	0.9900
17:81656487:ACT:A	donor_loss	0.9900
17:81656488:CTCA:C	donor_loss	0.9900
17:81656489:T:TA	donor_loss	0.9900
17:81656490:C:CC	donor_loss	0.9900
17:81656491:A:AC	donor_gain	0.9900
17:81656492:C:CC	donor_gain	0.9900
17:81653154:GCTTA:G	donor_loss	0.9800
17:81653155:CTTA:C	donor_loss	0.9800
17:81653156:TTAC:T	donor_loss	0.9800
17:81653157:TA:T	donor_loss	0.9800
17:81653158:ACCCT:A	donor_loss	0.9800
17:81653159:C:CA	donor_loss	0.9800
17:81653233:T:A	donor_gain	0.9800
17:81653283:G:C	donor_gain	0.9800
17:81653361:CGGT:C	acceptor_gain	0.9800
17:81656491:AC:A	donor_gain	0.9800
17:81656492:CC:C	donor_gain	0.9800
17:81656492:CCAA:C	donor_gain	0.9800
17:81651153:G:C	acceptor_gain	0.9700

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000320557 (17:81660735 G>A,T), RS1000375584 (17:81650124 T>C), RS1000746504 (17:81650362 A>C), RS1000968926 (17:81655158 C>T), RS1000990654 (17:81660529 CTGTTTTTTGTT>C), RS1001000019 (17:81654967 C>T), RS1001204735 (17:81657859 C>T), RS1001245088 (17:81650156 G>A,T), RS1001367416 (17:81660792 G>A), RS1001418119 (17:81661052 G>A), RS1001726515 (17:81655864 C>A), RS1002152317 (17:81653794 T>C), RS1002386995 (17:81663634 AT>A), RS1002434540 (17:81650736 G>A,T), RS1002526663 (17:81654005 G>T)

Disease associations

OMIM: gene MIM:180073 | disease phenotypes: MIM:613582, MIM:268000

GenCC curated gene-disease

Disease	Classification	Inheritance
retinitis pigmentosa 57	Definitive	Autosomal recessive
retinitis pigmentosa	Supportive	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
PDE6G-related retinopathy	Definitive	AR

Mondo (3): retinitis pigmentosa 57 (MONDO:0013315), retinitis pigmentosa (MONDO:0019200), inherited retinal dystrophy (MONDO:0019118)

Orphanet (2): Retinitis pigmentosa (Orphanet:791), OBSOLETE: Inherited retinal disorder (Orphanet:71862)

HPO phenotypes

39 total (30 of 39 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000007	Autosomal recessive inheritance
HP:0000405	Conductive hearing impairment
HP:0000407	Sensorineural hearing impairment
HP:0000501	Glaucoma
HP:0000505	Visual impairment
HP:0000510	Rod-cone dystrophy
HP:0000512	Abnormal electroretinogram
HP:0000543	Optic disc pallor
HP:0000546	Retinal degeneration
HP:0000551	Color vision defect
HP:0000563	Keratoconus
HP:0000602	Ophthalmoplegia
HP:0000613	Photophobia
HP:0000618	Blindness
HP:0000639	Nystagmus
HP:0000648	Optic atrophy
HP:0000662	Nyctalopia
HP:0000842	Hyperinsulinemia
HP:0001105	Retinal atrophy
HP:0001133	Constriction of peripheral visual field
HP:0001419	X-linked recessive inheritance
HP:0007663	Reduced visual acuity
HP:0007675	Progressive night blindness
HP:0007703	Abnormal retinal pigmentation
HP:0007737	Spicular pigmentation of the retina
HP:0007787	Posterior subcapsular cataract
HP:0007843	Attenuation of retinal blood vessels
HP:0007994	Peripheral visual field loss
HP:0008046	Abnormal retinal vascular morphology

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST006988_96	Blond vs. brown/black hair color	7.000000e-19
GCST009962_17	High myopia	2.000000e-13
GCST010002_133	Refractive error	2.000000e-50

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0003924	hair color

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D058499	Retinal Dystrophies	C11.768.585.658
D012174	Retinitis Pigmentosa	C11.270.684; C11.768.585.658.500; C16.320.290.684

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (3): CHEMBL2095220 (SELECTIVITY GROUP), CHEMBL2097163 (PROTEIN FAMILY), CHEMBL2363066 (PROTEIN FAMILY)

Molecules with ChEMBL bioactivity

6 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 154,266 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1520	VARDENAFIL	4	21,078
CHEMBL192	SILDENAFIL	4	41,819
CHEMBL779	TADALAFIL	4	23,417
CHEMBL932	DIPYRIDAMOLE	4	51,743
CHEMBL28079	ZAPRINAST	2	16,158
CHEMBL3109802	TBA-7371	2	51

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — Phosphodiesterases, 3’,5’-cyclic nucleotide (PDEs)

ChEMBL bioactivities

102 potent at pChembl≥5 of 110 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.00	IC50	0.1	nM	CHEMBL5081214
9.90	IC50	0.1259	nM	CHEMBL5080391
9.80	IC50	0.1585	nM	CHEMBL5087564
9.60	IC50	0.2512	nM	CHEMBL5094110
9.50	IC50	0.3162	nM	CHEMBL5086895
9.50	IC50	0.3162	nM	CHEMBL5076558
9.30	IC50	0.5	nM	SILDENAFIL
9.00	IC50	1	nM	VARDENAFIL
9.00	IC50	1	nM	CHEMBL5078680
9.00	IC50	1	nM	CHEMBL5088742
8.66	IC50	2.2	nM	CHEMBL2414311
8.13	IC50	7.4	nM	CHEMBL2180942
8.02	IC50	9.5	nM	SILDENAFIL
7.96	IC50	11	nM	VARDENAFIL
7.60	IC50	25	nM	SILDENAFIL
7.52	IC50	30.1	nM	CHEMBL4062273
7.40	IC50	40	nM	SILDENAFIL
7.30	Ki	50	nM	SILDENAFIL
7.21	IC50	62	nM	CHEMBL213060
7.14	IC50	73.15	nM	CHEMBL2069321
6.90	Ki	125	nM	DIPYRIDAMOLE
6.90	IC50	125	nM	CHEMBL282515
6.75	IC50	180	nM	CHEMBL373102
6.68	Ki	211	nM	CHEMBL1939800
6.65	IC50	226	nM	CHEMBL284070
6.60	IC50	249	nM	CHEMBL32255
6.57	IC50	271	nM	CHEMBL33518
6.56	IC50	276	nM	CHEMBL2070655
6.56	Ki	278	nM	CHEMBL1939803
6.55	IC50	280	nM	CHEMBL212397
6.48	IC50	330	nM	CHEMBL377563
6.48	IC50	330	nM	CHEMBL378255
6.48	IC50	330	nM	CHEMBL5434573
6.47	IC50	339	nM	CHEMBL2333219
6.46	IC50	349	nM	CHEMBL2070649
6.45	IC50	357	nM	CHEMBL418594
6.45	IC50	358	nM	CHEMBL33121
6.40	Ki	400	nM	ZAPRINAST
6.36	IC50	435	nM	CHEMBL2070639
6.33	IC50	462	nM	CHEMBL2070631
6.31	IC50	493	nM	CHEMBL2070651
6.31	IC50	494	nM	CHEMBL282515
6.26	IC50	550	nM	CHEMBL213219
6.26	Ki	554	nM	CHEMBL1939802
6.25	IC50	561	nM	CHEMBL4554391
6.21	IC50	610	nM	CHEMBL438451
6.21	IC50	620	nM	CHEMBL285737
6.16	IC50	693	nM	CHEMBL2070654
6.16	Ki	697	nM	CHEMBL1939804
6.13	IC50	734	nM	CHEMBL2070641

PubChem BioAssay actives

102 with measured affinity, of 185 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
[(1S)-1-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-(3,5-dichloro-1-oxidopyridin-1-ium-4-yl)ethyl] 3-[[2-[[(3R)-1-azabicyclo[2.2.2]octan-3-yl]oxy]-2-oxo-1-phenylethyl]sulfamoyl]benzoate	1812119: Inhibition of PDE4 in human U-937 cells assessed as reduction in cAMP level by LANCE cAMP Assay	ic50	0.0001	uM
[(1S)-1-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-(3,5-dichloro-1-oxidopyridin-1-ium-4-yl)ethyl] 3-[[N-[[(3R)-1-azabicyclo[2.2.2]octan-3-yl]oxycarbonyl]anilino]methyl]benzoate	1812119: Inhibition of PDE4 in human U-937 cells assessed as reduction in cAMP level by LANCE cAMP Assay	ic50	0.0001	uM
[(1S)-2-(3,5-dichloro-1-oxidopyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl] 3-[[2-[[(3R)-1-azabicyclo[2.2.2]octan-3-yl]oxy]-2-oxo-1-phenylethyl]amino]benzoate	1812119: Inhibition of PDE4 in human U-937 cells assessed as reduction in cAMP level by LANCE cAMP Assay	ic50	0.0002	uM
[(1S)-2-(3,5-dichloro-1-oxidopyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl] 3-[[[2-[[(3R)-1-azabicyclo[2.2.2]octan-3-yl]oxy]-2-oxo-1-phenylethyl]amino]methyl]benzoate	1812119: Inhibition of PDE4 in human U-937 cells assessed as reduction in cAMP level by LANCE cAMP Assay	ic50	0.0003	uM
[(1S)-2-(3,5-dichloro-1-oxidopyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl] 3-[[2-[[(3R)-1-azabicyclo[2.2.2]octan-3-yl]oxy]-2-oxo-1-phenylethyl]sulfamoyl]benzoate	1812119: Inhibition of PDE4 in human U-937 cells assessed as reduction in cAMP level by LANCE cAMP Assay	ic50	0.0003	uM
[(1S)-1-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-(3,5-dichloro-1-oxidopyridin-1-ium-4-yl)ethyl] 3-[[[2-[[(3R)-1-azabicyclo[2.2.2]octan-3-yl]oxy]-2-oxo-1-phenylethyl]amino]methyl]benzoate	1812119: Inhibition of PDE4 in human U-937 cells assessed as reduction in cAMP level by LANCE cAMP Assay	ic50	0.0003	uM
Sildenafil	735483: Inhibition of PDE6 (unknown origin) using FAM-cGMP as substrate after 60 mins by fluorescence assay	ic50	0.0005	uM
Vardenafil	240962: Inhibition of human phosphodiesterase 6	ic50	0.0010	uM
[(1S)-2-(3,5-dichloro-1-oxidopyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl] 3-[[N-[[(3R)-1-azabicyclo[2.2.2]octan-3-yl]oxycarbonyl]anilino]methyl]benzoate	1812119: Inhibition of PDE4 in human U-937 cells assessed as reduction in cAMP level by LANCE cAMP Assay	ic50	0.0010	uM
[(1S)-1-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-(3,5-dichloro-1-oxidopyridin-1-ium-4-yl)ethyl] 3-[[2-[[(3R)-1-azabicyclo[2.2.2]octan-3-yl]oxy]-2-oxo-1-phenylethyl]amino]benzoate	1812119: Inhibition of PDE4 in human U-937 cells assessed as reduction in cAMP level by LANCE cAMP Assay	ic50	0.0010	uM
(2S)-1-[3-(5-bromo-6-oxo-4-propan-2-yl-1H-pyrimidin-2-yl)-4-propoxyphenyl]sulfonylpyrrolidine-2-carboxylic acid	764685: Inhibition of PDE6 (unknown origin)	ic50	0.0022	uM
5-bromo-2-[5-(4-methylpiperazin-1-yl)sulfonyl-2-propoxyphenyl]-4-propan-2-yl-1H-pyrimidin-6-one	764685: Inhibition of PDE6 (unknown origin)	ic50	0.0074	uM
2-acetyl-10-[(3-chloro-4-methoxyphenyl)methylamino]-3,4-dihydro-1H-benzo[b][1,6]naphthyridine-8-carbonitrile	1866074: Inhibition of PDE6 (unknown origin) using FAM-cGMP or FAM-cAMP as substrate incubated for 60 mins and measured by fluorescence polarization assay	ic50	0.0301	uM
11-benzyl-13-methyl-4-phenyl-7-propan-2-yl-5,6,8,11,12-pentazatricyclo[7.4.0.02,6]trideca-1(9),2,4,7,12-pentaen-10-one	269694: Inhibition of PDE6	ic50	0.0620	uM
1-(2-chlorophenyl)-6,8-dimethoxy-3-methylimidazo[5,1-c][1,2,4]benzotriazine	678635: Inhibition of PDE6	ic50	0.0732	uM
Dipyridamole	238297: Inhibition of human phosphodiesterase 6	ki	0.1250	uM
(2R,8R)-2-(1,3-benzodioxol-5-yl)-6-[(3R)-1-[2-(1-methylimidazol-2-yl)ethyl]pyrrolidin-3-yl]-3,6,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraene-4,7-dione	158129: Inhibitory activity against phosphodiesterase 6 (PDE6) obtained from canine or bovine retina	ic50	0.1250	uM
(7R)-7-benzyl-2-bromo-5-ethyl-3-[(4-hydroxyphenyl)methyl]-7,8-dihydroimidazo[2,1-b]purin-4-one	240962: Inhibition of human phosphodiesterase 6	ic50	0.1800	uM
6-methoxy-3,8-dimethyl-N-(pyridin-4-ylmethyl)-2H-pyrazolo[3,4-b]quinolin-4-amine	640658: Inhibition of recombinant human PDE6 using [3H]cAMP as substrate by scintillation proximity assay	ki	0.2110	uM
(2R,8R)-2-(1,3-benzodioxol-5-yl)-6-[(3R)-1-(2-pyridin-2-ylethyl)pyrrolidin-3-yl]-3,6,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraene-4,7-dione	158129: Inhibitory activity against phosphodiesterase 6 (PDE6) obtained from canine or bovine retina	ic50	0.2260	uM
(2R,8R)-2-(1,3-benzodioxol-5-yl)-6-[(3R)-1-benzylpyrrolidin-3-yl]-3,6,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraene-4,7-dione	158129: Inhibitory activity against phosphodiesterase 6 (PDE6) obtained from canine or bovine retina	ic50	0.2490	uM
(2R,8R)-2-(1,3-benzodioxol-5-yl)-6-[(3R)-1-(2-pyridin-3-ylethyl)pyrrolidin-3-yl]-3,6,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraene-4,7-dione	158129: Inhibitory activity against phosphodiesterase 6 (PDE6) obtained from canine or bovine retina	ic50	0.2710	uM
4-[1-(2-chlorophenyl)-6-methoxy-3-methylimidazo[5,1-c][1,2,4]benzotriazin-8-yl]morpholine	678635: Inhibition of PDE6	ic50	0.2760	uM
6-methoxy-3,8-dimethyl-N-(oxan-4-yl)-2H-pyrazolo[3,4-b]quinolin-4-amine	640658: Inhibition of recombinant human PDE6 using [3H]cAMP as substrate by scintillation proximity assay	ki	0.2780	uM
11-benzyl-7,13-dimethyl-4-pyridin-3-yl-5,6,8,11,12-pentazatricyclo[7.4.0.02,6]trideca-1(9),2,4,7,12-pentaen-10-one	269694: Inhibition of PDE6	ic50	0.2800	uM
11-benzyl-4-(furan-3-yl)-7,13-dimethyl-5,6,8,11,12-pentazatricyclo[7.4.0.02,6]trideca-1(9),2,4,7,12-pentaen-10-one	269694: Inhibition of PDE6	ic50	0.3300	uM
11-benzyl-13-(ethoxymethyl)-7-methyl-4-phenyl-5,6,8,11,12-pentazatricyclo[7.4.0.02,6]trideca-1(9),2,4,7,12-pentaen-10-one	269694: Inhibition of PDE6	ic50	0.3300	uM
N-(2-pyrazin-2-yl-4,6-dihydrothieno[3,4-c]pyrazol-3-yl)naphthalene-1-carboxamide	1994821: Inhibition of PDE (unknown origin)	ic50	0.3300	uM
4-[(3-chloro-4-methoxyphenyl)methylamino]-8-cyclopropyl-3-(hydroxymethyl)quinoline-6-carbonitrile	1866074: Inhibition of PDE6 (unknown origin) using FAM-cGMP or FAM-cAMP as substrate incubated for 60 mins and measured by fluorescence polarization assay	ic50	0.3390	uM
6,8-dimethoxy-3-methyl-1-(2-methylphenyl)imidazo[5,1-c][1,2,4]benzotriazine	678635: Inhibition of PDE6	ic50	0.3490	uM
(2R,8R)-2-(1,3-benzodioxol-5-yl)-6-[(3R)-1-[2-(1H-imidazol-2-yl)ethyl]pyrrolidin-3-yl]-3,6,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraene-4,7-dione	158129: Inhibitory activity against phosphodiesterase 6 (PDE6) obtained from canine or bovine retina	ic50	0.3570	uM
(2R,8R)-2-(1,3-benzodioxol-5-yl)-6-[(3R)-1-(2-pyrazin-2-ylethyl)pyrrolidin-3-yl]-3,6,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraene-4,7-dione	158129: Inhibitory activity against phosphodiesterase 6 (PDE6) obtained from canine or bovine retina	ic50	0.3580	uM
5-(2-propoxyphenyl)-2,6-dihydrotriazolo[4,5-d]pyrimidin-7-one	238389: Inhibition of human phosphodiesterase 6	ki	0.4000	uM
3-(2-chlorophenyl)-12-methoxy-5-methyl-2,4,7,8,13-pentazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaene	678635: Inhibition of PDE6	ic50	0.4350	uM
3-(2-chloro-4-fluorophenyl)-12-methoxy-5-methyl-2,4,7,8,13-pentazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaene	678635: Inhibition of PDE6	ic50	0.4620	uM
6,8-dimethoxy-3-methyl-1-(2-methyl-3-pyridinyl)imidazo[5,1-c][1,2,4]benzotriazine	678635: Inhibition of PDE6	ic50	0.4930	uM
11-benzyl-7-ethyl-13-methyl-4-phenyl-5,6,8,11,12-pentazatricyclo[7.4.0.02,6]trideca-1(9),2,4,7,12-pentaen-10-one	269694: Inhibition of PDE6	ic50	0.5500	uM
6-methoxy-3,8-dimethyl-N-(2-pyridin-4-ylethyl)-2H-pyrazolo[3,4-b]quinolin-4-amine	640658: Inhibition of recombinant human PDE6 using [3H]cAMP as substrate by scintillation proximity assay	ki	0.5540	uM
1-[[2-(7-fluoro-3-methylquinoxalin-2-yl)-5-[(3R)-3-fluoropyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-7-yl]amino]-2-methylpropan-2-ol;hydrochloride	1552322: Inhibition of PDE6 (unknown origin)	ic50	0.5610	uM
11-benzyl-13-methyl-4-phenyl-7-propyl-5,6,8,11,12-pentazatricyclo[7.4.0.02,6]trideca-1(9),2,4,7,12-pentaen-10-one	269694: Inhibition of PDE6	ic50	0.6100	uM
3-[(3R)-3-[(2R,8R)-2-(1,3-benzodioxol-5-yl)-4,7-dioxo-3,6,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraen-6-yl]pyrrolidin-1-yl]-N-ethylpropanamide	158129: Inhibitory activity against phosphodiesterase 6 (PDE6) obtained from canine or bovine retina	ic50	0.6200	uM
4-[6-methoxy-3-methyl-1-(2-methylphenyl)imidazo[5,1-c][1,2,4]benzotriazin-8-yl]morpholine	678635: Inhibition of PDE6	ic50	0.6930	uM
6-methoxy-3,8-dimethyl-N-(oxan-4-ylmethyl)-2H-pyrazolo[3,4-b]quinolin-4-amine	640658: Inhibition of recombinant human PDE6 using [3H]cAMP as substrate by scintillation proximity assay	ki	0.6970	uM
3-(2-fluoro-5-methoxyphenyl)-12-methoxy-5-methyl-2,4,7,8,13-pentazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaene	678635: Inhibition of PDE6	ic50	0.7340	uM
3-[(3R)-3-[(2R,8R)-2-(1,3-benzodioxol-5-yl)-4,7-dioxo-3,6,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraen-6-yl]pyrrolidin-1-yl]-N,N-dimethylpropanamide	158129: Inhibitory activity against phosphodiesterase 6 (PDE6) obtained from canine or bovine retina	ic50	0.8070	uM
3-(2,5-dichlorophenyl)-12-methoxy-5-methyl-2,4,7,8,13-pentazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaene	678635: Inhibition of PDE6	ic50	0.8290	uM
6-methoxy-3,8-dimethyl-N-(oxan-2-ylmethyl)-2H-pyrazolo[3,4-b]quinolin-4-amine	640658: Inhibition of recombinant human PDE6 using [3H]cAMP as substrate by scintillation proximity assay	ki	0.8430	uM
(2R,8R)-6-[(3R)-1-[3-(azetidin-1-yl)-3-oxopropyl]pyrrolidin-3-yl]-2-(1,3-benzodioxol-5-yl)-3,6,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraene-4,7-dione	158129: Inhibitory activity against phosphodiesterase 6 (PDE6) obtained from canine or bovine retina	ic50	0.8460	uM
11-benzyl-13-methyl-4-phenyl-5,6,8,11,12-pentazatricyclo[7.4.0.02,6]trideca-1(9),2,4,7,12-pentaen-10-one	269694: Inhibition of PDE6	ic50	0.8600	uM
8-(difluoromethoxy)-6-methoxy-3-methyl-1-(3-methyl-4-pyridinyl)imidazo[5,1-c][1,2,4]benzotriazine	678635: Inhibition of PDE6	ic50	0.9090	uM

CTD chemical–gene interactions

11 total (human), top 11 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
aristolochic acid I	increases expression	1
butyraldehyde	increases expression	1
bisphenol S	decreases methylation	1
jinfukang	affects cotreatment, increases expression	1
Glyphosate	increases expression	1
Amiodarone	increases expression	1
Benzo(a)pyrene	affects methylation	1
Cisplatin	affects cotreatment, increases expression	1
Phthalic Acids	increases methylation	1
Aflatoxin B1	increases methylation	1
Okadaic Acid	decreases expression	1

ChEMBL screening assays

51 unique, capped per target: 49 binding, 2 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL832228	Binding	Relative binding to Phosphodiesterase 6 and Phosphodiesterase 5, ratio of IC50	Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED. — Bioorg Med Chem Lett
CHEMBL4348841	ADMET	Inhibition of PDE6 (unknown origin)	Structure Overhaul Affords a Potent Purine PI3Kδ Inhibitor with Improved Tolerability. — J Med Chem

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_1581	NCI-H716	Cancer cell line	Male

Clinical trials (associated diseases)

259 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00717080	PHASE4	COMPLETED	The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction
NCT00000114	PHASE3	COMPLETED	Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa
NCT00000116	PHASE3	COMPLETED	Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A
NCT00346333	PHASE3	COMPLETED	Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A
NCT01786395	PHASE3	TERMINATED	Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa
NCT04224207	PHASE3	COMPLETED	Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton’s Jelly Derived Mesenchymal Stem Cells
NCT04636853	PHASE3	COMPLETED	CB-PRP in Retinitis Pigmentosa and Dry Age-related Macular Degeneration
NCT05537220	PHASE3	ACTIVE_NOT_RECRUITING	Oral N-acetylcysteine for Retinitis Pigmentosa
NCT05800301	PHASE3	COMPLETED	Management of Retinitis Pigmentosa Via Combination of Wharton’s Jelly-derived Mesenchymal Stem Cells and Magnovision
NCT05926583	PHASE3	ACTIVE_NOT_RECRUITING	A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa
NCT06388200	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
NCT07082855	PHASE3	NOT_YET_RECRUITING	A Multicenter, Randomized, Double-Blind, Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa
NCT07290530	PHASE3	NOT_YET_RECRUITING	24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
NCT00100230	PHASE2	COMPLETED	DHA and X-Linked Retinitis Pigmentosa
NCT00447980	PHASE2	COMPLETED	A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
NCT00447993	PHASE2	COMPLETED	A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa
NCT01233609	PHASE2	COMPLETED	Trial of Oral Valproic Acid for Retinitis Pigmentosa
NCT01399515	PHASE2	COMPLETED	Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa
NCT01530659	PHASE2	COMPLETED	Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa
NCT01560715	PHASE2	COMPLETED	Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa
NCT02609165	PHASE2	COMPLETED	Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema
NCT02661711	PHASE2	COMPLETED	Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study
NCT02804360	PHASE2	UNKNOWN	Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Macular Edema- a Retrospective Study
NCT02837640	PHASE2	UNKNOWN	Studying a Potential Protective Effect of L-Dopa on Retinitis Pigmentosa
NCT03073733	PHASE2	COMPLETED	Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa
NCT04068207	PHASE2	COMPLETED	Minocycline Treatment in Retinitis Pigmentosa
NCT04356716	PHASE2	COMPLETED	Sildenafil for Treatment of Choroidal Ischemia
NCT04604899	PHASE2	COMPLETED	Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa
NCT04763369	PHASE2	UNKNOWN	Investigation of Therapeutic Efficacy and Safety of UMSCs for the Management of Retinitis Pigmentosa (RP)
NCT04864496	PHASE2	UNKNOWN	Effects of Treatment With N- Acetylcysteine on Visual Outcomes in Patients With Retinitis Pigmentosa
NCT04945772	PHASE2	COMPLETED	Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
NCT05085964	PHASE2	TERMINATED	An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
NCT05392179	PHASE2	COMPLETED	A Study in Subjects With Retinitis Pigmentosa
NCT06627179	PHASE2	RECRUITING	Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
NCT06628947	PHASE2	RECRUITING	A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
NCT06912633	PHASE2	RECRUITING	Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
NCT03763227	PHASE2	COMPLETED	Intravitreal Ranibizumab (Lucentis®) in the Treatment of Non-leaking Macular Cysts in Retinal Dystrophy
NCT00063765	PHASE1	COMPLETED	Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye
NCT00065455	PHASE1	COMPLETED	Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa
NCT00458575	PHASE1	TERMINATED	A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa